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Abstract 
Steroid-resistant nephrotic syndrome (SRNS), a heterogeneous disorder of the renal 
glomerular filtration barrier results in impairment of glomerular permselectivity.  Inheritance 
of genetic SRNS may be autosomal dominant or recessive, with a subset of autosomal 
recessive SRNS presenting as congenital nephrotic syndrome (CNS). Currently mutations in 
53 genes are associated with human SRNS yet these explain no more than 30% of 
hereditary and only 20% of sporadic cases. The encoded proteins are expressed in 
podocytes and malfunction leads to a universal end point of podocyte injury, glomerular 
filtration barrier disruption and SRNS. Although MAGI2, (Membrane Associated Guanylate 
Kinase, WW And PDZ Domain Containing 2) was recently shown to interact with nephrin 
and regulate the podocyte cytoskeleton and slit diaphragm dynamics, MAGI2 mutations 
have not been previously described in human SRNS.  Here, we identify novel disease 
causing mutations in MAGI2 through whole exome sequencing of a deeply phenotyped 
cohort of childhood onset SRNS, resulting in congenital onset SRNS. Two unique frameshift 
mutations and one duplication were detected in three patients (2 families), two siblings 
shared the same homozygous frameshift mutation whereas one sporadic case exhibited 
compound heterozygosity. Two mutations were predicted to introduce premature stop 
codons and one to result in read-through of the normal translational termination codon. 
Mutations resulted in lack or diminished expression of podocyte MAGI2 expression. Our data 
supports the novel finding that mutations in the MAGI2 gene are causal for congenital 
SRNS.  
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Introduction 
Steroid-resistant nephrotic syndrome (SRNS), a disorder of glomerular filtration results in 
severe proteinuria, hypoalbuminaemia and oedema. Currently, 53 genes are implicated 
(Table S1) but these account for only 20–30% of hereditary and only 10–20% of sporadic 
cases supporting significant genetic heterogeneity. 1-8 To date, all known SRNS-associated 
genes encode proteins expressed in podocytes (or associated basement membrane), 
polarised cells connected by highly specialised junctions called slit diaphragms. Correct 
podocyte morphology is essential for maintaining GFB integrity and the podocyte actin 
cytoskeleton is tightly regulated by cell surface receptors including the multi-protein complex 
at the slit diaphragm. Known SRNS gene mutations disrupt key cellular functions resulting in 
podocyte injury and disruption of glomerular permselectivity. Typically, patients with a 
mutation in an SRNS-associated gene are less likely to respond to immunosuppressive 
treatment, but have a reduced risk of disease recurrence post kidney transplant.9 SRNS may 
present at birth (Congenital Nephrotic Syndrome, CNS), usually with an early and severe 
phenotype with about 80%10 of cases ascribed to only 6 causal genes: NPHS1, NPHS2, 
LAMB2, WT1, PLCE1, and LMX1B11, all key players in podocyte biology – the genetic cause 
of the remainder is unknown. The majority of SRNS cases in childhood have an autosomal 
recessive mode of inheritance. 
 
Results 
Screening the known nephrotic genes  
We expanded the study originally described in McCarthy et al1 and performed whole exome 
sequencing on a deeply phenotyped cohort of 187 childhood SRNS cases (onset < 18 years, 
11.8% familial, 7% consanguineous, 48.7% female, 51.3% male, 69.5% Caucasian, 30.5% 
south Asian, mixed race, African and East Asian) collected via a UK-wide Registry.  
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First, the cohort was screened for presence of disease causing mutations in the 53 
published genes known to be associated with SRNS (Table S1; mapping statistics are 
presented in Table S2). Our findings correlated with previous published studies2, 12 in that 
mutations in known SRNS genes were only detected in approximately 25% of cases. 
Assuming that mutations in the exome were present in a proportion of the remaining 75% of 
cases, variants detected in the whole exome were filtered to identify potential mutations in 
genes previously not directly associated with SRNS. 
 
MAGI2 mutations identified by whole exome sequencing 
After filtering and further analysis of potentially pathogenic mutations in genes not previously 
directly associated with SRNS, we identified three novel, likely disease causing frameshift 
mutations (Figure 1) in Membrane associated guanylate kinase, WW and PDZ domain 
containing 2 (MAGI2 [MIM: 606382]) in one sporadic case (180, Figure S4) and two familial 
cases (175 and 175S, Figure S5) presenting with non-syndromic congenital SRNS. As 
parents of patient 175 and 175S were consanguineous, autosomal recessive inheritance 
was considered the most likely mechanism of inheritance.  
Whole exome sequencing was performed on patient 175 and 180. Subsequent segregation 
analysis confirmed that two siblings (175 and 175S) shared the same homozygous 
frameshift deletion MAGI-2:NM_012301:exon22:c.3998delG:p.(Gly1333Alafs*141). The 
sporadic case (180) exhibited compound heterozygosity: a deletion (paternal) resulting in a 
premature stop codon MAGI-2:NM_012301:exon1:c.64_71delAGGAACCC:p.(Arg22Glyfs*7) 
together with a duplication (maternal) MAGI-
2:NM_012301:exon20:c.3526_3533dupCTGGCAGA:p.(Glu1178Aspfs*9). All three variants 
were absent in ExAC database, had high CADD scores (34 (175, 175S), 35 and 35 (180)) 
respectively supporting pathogenicity of these mutations. Translation of the mutated protein 
(ExPASy http://web.expasy.org/translate) indicated that the two frameshift mutations located 
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in exon 1 and exon 20 resulted in stop codons and premature termination of protein 
translation and were located in PDZ domains. The exon 22 frameshift deletion resulted in 
predicted read through of the normal termination (stop) codon, resulting in likely continued 
translation of the mRNA further downstream into the 3'-untranslated region (UTR).  
Cases 175, 175S and 180 did not demonstrate any other significant rare or novel variants in 
other genes expressed in podocytes during exome screening supporting MAGI2 as the most 
likely causative gene. Furthermore, there were no rare frameshift mutations at the same site 
as any of the MAGI2 mutations within 100bp in Ensembl or other public databases, although 
one in-house control carried a heterozygous frameshift insertion in exon 
20:c.3512_3513insTGTA:p.(Leu1171Phefs*27). Other MAGI2 variants were not detected in 
these or other control samples. 
The MAGI2 homozygous frame shift deletion p.(Gly1333Alafs*141) was verified by Sanger 
sequencing and this was only homozygous variant present in both 175 and 175S. It was also 
present in the mother (175M) as a heterozygote but could not be verified in the father as 
DNA was not available.  
Of the eight rare/novel variants found in 175, two (RAD51D, NUP155) were absent in 175S 
and the other two (GABRD, POLR2M) were only present as heterozygous variants.  
Furthermore, one variant (AKR1C1) was present as homozygous in the ExAC database and 
one (IGLL5) was predicted to be tolerated by in silico tools; excluding both as likely 
candidates. Both heterozygous variants in SKOR1 found in 175 were inherited from the 
mother and thus present on the same allele. Only one rare heterozygous potential known 
SRNS gene variant was shared by the siblings: COL4A3 c.4421T>C:p.(Leu1474Pro), 
detected prior to enrolment to the study by the Bristol Genetics Laboratory (SRNS 37 gene 
panel, www.nbt.nhs.uk/severn-pathology/pathology-services/bristol-genetics-laboratory-bgl). 
This variant was seen over 300 times as a heterozygote in ExAC database and is therefore 
of unlikely significance.  
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Since DNA from both parents was available for 180, we were able to verify that the novel 
MAGI2 mutations were in trans; p.(Arg22Glyfs*7) was inherited on a paternal allele and 
p.(Glu1178Aspfs*9) on a maternal allele. The frame shift variations in MAGI2 were not 
present in the ExAC database. Six other nonsense variants in MAGI2 were present; however 
each seen only once and as a heterozygote. Similarly one splice acceptor and two splice 
donor variants are also present in the ExAC database but again, only present as 
heterozygotes. If we include non-PASS variants an additional nonsense and 3 frameshift 
variants are also present, however again, all were seen only as heterozygotes.  
5 other genes were also left after the filtering steps; however, variants in three genes were 
maternally inherited in cis, and insertions in MICALCL and ZIC5 were considered of unlikely 
significance due to presence of similar insertions around this region in ExAC database. 
MAGI2 remained the sole candidate gene for causing nephrotic syndrome in our patients. 
(Data is presented in Table S3) 
There was no associated extra-renal phenotype in patient 175 while 175S had some minor 
cardiac (possibly unrelated) abnormalities. Case 180 had associated polydactyly and a 
previous pyloric stenosis, although did not demonstrate any other features of any 
characterised syndrome. The inheritance pattern in all three cases was compatible with 
autosomal recessive disease. All had presented with significant proteinuria and 
hypoalbuminaemia within the first 4 months of life compatible with a CNS. Patient 175 was 
diagnosed after renal biopsy with ‘Finnish type’ nephrotic syndrome which is usually caused 
by NPHS1 mutations, but the renal histology in early life may be relatively non-specific in 
appearance and no NPHS1 mutations were detected on screening the entire gene. Patient 
175 had rapid disease progression and required a kidney transplant at age 3.5 years; in 
contrast the sibling, 175S, has followed a more benign course. Similarly patient 180 has had 
persistent proteinuria for 9 years with only mild renal impairment to date. Phenotypic 
variability between different family members is not unusual in SRNS and has been 
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previously described  Interestingly, the most severely affected patient (175) also carried a 
single heterozygous variant in LAMB2 resulting in c.4274G>C:p.(Gly1425Ala), the 
significance of which is unknown but was not present as a homozygote on the ExAC 
database and had a MAF of 0.000075. Disease modification due to bi-genic heterozygosity 
or or tri-allelic hits may occur, but is unusual in SRNS.13 Phenotypic details are presented in 
Table 1. 
 
Immunohistochemistry: 
Kidney biopsy sections (from individual 180 and an individual with MCD), a nephrectomy 
section from individual 175 and from an unsuitable for transplant normal human kidney 
sections used for IHC were formalin fixed and paraffin embedded.  
 
Glomeruli from patient 175 showed marked lobulation, with fibrosis or global sclerosis, 
interstitial fibrosis and diffuse inflammation. From patient 180, changes were milder 
(consistent with milder renal impairment), with 2/59 glomeruli showing global sclerosis and 
the rest looking normal on light microscopy. Electron microscopy (supplemental Figure S3) 
from this specimen shows a normal mesangial area, normal glomerular basement 
membrane, and diffuse podocyte foot process effacement, similar to the reported mouse 
model14.  
MAGI2 staining was absent in case 180, consistent with an early truncation resulting in non-
translation of the MAGI2 protein through nonsense mediated decay. MAGI2 staining was 
however weakly positive in podocytes of case 175. The terminal position of the frame shift 
mutation (exon 22) and predicted read through into the 3’ UTR supports weak expression of 
a translated yet dysfunctional protein. 
We observed MAGI2 staining in the tubules in control sections, which was absent in case 
180 with this antibody (Sigma). We therefore stained sections with a different antibody 
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(Santa Cruz) which showed different degrees of tubular staining in all sections, weak 
glomerular staining in the normal kidney, weak/negative staining in case 175 and negative 
staining in case 180 (Figure S2). The ‘best fit’ explanation for the difference in tubular 
staining with the Santa Cruz antibody is that this is due to a component of non-specific 
staining with this antibody, so we cannot be conclusive about the specificity of tubular 
staining. 
Nephrin expression appeared to be decreased and localisation altered in both 175 and 180 
patients compared to control, and similar to what was observed in MAGI2 mouse models.15, 
16 
 
Discussion 
We performed whole exome sequencing using an Illumina platform on 187 SRNS cases as 
an extension of previous analysis of a cohort of childhood SRNS1. Cases lacking mutations 
in the known 53 nephrotic genes were analysed further in particular those with congenital 
nephrotic syndrome which is generally autosomal recessive and a developmental disorder. 
The exome data was therefore analysed to look for novel candidate genes. After filtering and 
further analysis of potentially pathogenic mutations in genes expressed in podocytes but not 
previously directly associated with SRNS, we identified likely disease causing frameshift 
mutations in MAGI2 in one sporadic case (180) and two familial cases (175 and 175S). 
Although a recently ascribed podocyte gene, MAGI2 mutations have been not previously 
been directly associated with human SRNS. MAGI2 together with its paralogues MAGI1 and 
MAGI3 belong to the membrane-associated guanylate kinase (MAGUK) family of scaffolding 
proteins highly expressed in neurones and normally associated with neurological function 17-
19. MAGI proteins function as molecular scaffolds coordinating signalling complexes by 
linking cell surface receptors to the cytoskeleton but differ from other members of the 
MAGUK family by having a guanylate kinase (GK) domain at the N-terminus as well as WW 
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and PDZ domains in reverse orientation to MAGUK20. MAGI2 is expressed in podocyte foot 
processes together with IQGAP1, CASK, spectrins and α-actinin and is known to directly 
bind the cytosolic tail of nephrin, an essential component of the slit diaphragm, as part of the 
nephrin multi-protein complex21. It also plays a role in RhoA dependent regulation of the 
actin cytoskeleton, an important process in podocytes22. Moreover, MAGI2 has recently 
been described as a WT1 target gene and required for podocyte development both in 
zebrafish23 and mice. Mice with MAGI2 deletion display disruption of the slit diaphragm 
formation, podocyte foot process effacement, severe glomerular pathology compatible with 
human SRNS, with early death from nephrotic syndrome and kidney failure16. In humans, 
expression data from micro-dissected renal biopsies (Nephromine 
http://www.nephromine.org/) indicated MAGI2 was one of the top deregulated genes in 
glomerular disease with a 3.2-fold and 6.2-fold decrease in focal segmental 
glomerulosclerosis (FSGS) and diabetic nephropathy respectively, further underlining its 
potential importance in human SRNS.15 
Aside from published evidence that MAGI2 is a component of the multi-protein complex at 
the slit diaphragm, MAGI2 deleted mice die soon after birth from podocyte injury, severe 
proteinuria and end stage renal failure, indicating a profound developmental slit diaphragm 
defect17,19,20,22. Furthermore, MAGI2 is a WT1 target during podocyte development and has 
been previously implicated in RhoA regulation/signalling known to play a critical role in actin 
cytoskeletal regulation in podocytes. 23 22 24 25   
In conclusion, we present genetic data that supports MAGI2 mutations as a cause of 
congenital SRNS in humans. Although further functional studies are required to establish 
exactly how MAGI2 mutations lead to human CNS, we propose MAGI2 gene mutations 
should be added to gene panels when investigating SRNS, and considered in patients with 
congenital onset SRNS, particularly where mutation in other known genes is not found. 
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Methods 
Sequencing 
Patients 175 and 180 underwent exome sequencing. DNA from peripheral blood was 
extracted Gentra Puregene Blood Kit (Qiagen).  DNA libraries were prepared from 3 µg 
dsDNA using SureSelect Human All Exon 50Mb kit (Agilent).  Samples were multiplexed (4 
samples on each lane) and 100 bp paired end sequencing was performed on Illumina HiSeq 
system. Sequence data was aligned to the hg19 human reference genome using Novoalign 
(Novocraft Technologies SDN BHD, Malaysia), variants were called with SAMtools 
(Sequence Alignment/Map Tools)26 and annotated via multiple passes through Annovar27. 
Initial exploration of datasets was performed using Integrative Genome Browser 
(https://www.broadinstitute.org/igv). 
Variant filtering 
1. Only variants with a MAF <0.01 were considered (1000 Genomes Project 
http://www.1000genomes.org/, NHLBI Exome Sequencing Project (ESP 
http://evs.gs.washington.edu/EVS/), http://exac.broadinstitute.org/, KCL in-house 
data set (King’s College London, in-house data from 5000 control individuals without 
kidney disease)). 
2. Variants seen as a homozygote in ExAC database, ESP or 1000 Genomes Project 
were excluded from further analysis. 
3. For the novel/not previously described missense variants, information from Alamut 
Visual http://interactive-biosoftware.com/alamut-visual and UCSC 
http://genome.ucsc.edu/ was used to check whether an amino acid is conserved – 
For filtering, the amino acid must be conserved and the new amino acid must not be 
present in another multicellular organism.  
4. Analysis of potential synonymous and splice site variants using Alamut Visual 2.7 
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing 
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Finder) to check if there was a consistent predicted splice effect across the majority 
of tools. MAGI2 frameshift mutations were examined for deleteriousness using CADD 
http://cadd.gs.washington.edu. 
5. Variants present within 50bp and subsequently shown to be present in cis were 
excluded and not considered compound heterozygotes.  
6. Any variants that did not meet criteria above were discarded 
7. All mutations of interest were confirmed by Sanger sequencing in probands and 
parents. 
 
To ascertain further annotative information about potential genes of interest we also 
examined genomic, proteomic, transcriptomic, genetic and functional information on all new 
candidates using databases such as GeneCards http://www.genecards.org/, Ensembl 
http://ensembl.org    and Uniprot http://www.uniprot.org  as well as the Human Protein Atlas 
http://www.proteinatlas.org/  and literature searches to help decisions regarding potential 
pathogenicity of findings. Mouse Genome Informatics (MGI http://www.informatics.jax.org/) 
was used for murine data and establishing whether SRNS disease phenotypes might occur 
in mice. Further details are provided in Table S3 and S4. 
 
Immunohistochemistry: 
Two MAGI2 antibodies were used: 
MAGI2 (Sigma, #HPA013650) was used 1:250. Heat-induced epitope retrieval was 
performed using a domestic stainless steel pressure cooker. 5 minutes were counted as 
soon as the cooker has reached full pressure. (10mM Sodium citrate tribasic pH 6). 10% 
goat serum (Sigma) was used for blocking.  
MAGI2 (Santa Cruz, #sc-25664) was used 1:50. Heat induced antigen retrieval method was 
used (boiled for 5 min, 10mM Sodium citrate tribasic pH 6). 3% BSA + 3% goat serum was 
used for blocking. 
12 
 
Fluorescent Immunohistochemistry staining of paraffin-embedded tissue sections. 
Nephrin (R&D, #AF4269) was used 1:200. Donkey anti-sheep IgG (H+L) secondary 
antibody, Alexa Fluor® 488 conjugate (Life Technologies, #A11015) was used in 1:300. 
Proteinase K was used as antigen retrieval (20µg/ml). 1.5% BSA (Sigma, #A9647) plus 5% 
donkey serum (SIGMA, # D9663) was used for blocking. 
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Figures and Tables 
 
Figure 1. MAGI2 mutations causing Congenital Nephrotic Syndrome. 
A. The exon structure of MAGI2 cDNA (NM_012301.3). 22 coding exons with start and stop codon indicated. 
B. Domain structure of the MAGI2 protein. Six PDZ domains (PDZ0-PDZ5) in blue, one guanylate kinase domain 
(GK) in yellow and two WW domains in green. 
C. Frame shift variants found in three patients with CNS. Individual 180 is a compound heterozygote, variant in 
exon 1 was inherited from the Father and in exon 20 from the Mother. Individual 175 and her sister, 175S, are 
homozygous for a single nucleotide deletion in exon 22. Mother of the siblings is heterozygous for the variant. 
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Patient 
# 
Gender Ethnicity 
Familial / 
Sporadic 
Age 
at 
onset 
Consanguinity 
Resistance 
to steroids 
1st  
native 
biopsy 
2nd 
native 
biopsy 
CKD 
stage 
Time 
to 
ESRF 
Transplanted? 
Disease 
recurrence? 
Extra-renal 
phenotype 
Treatment 
used 
Most 
recent 
Serum 
Creatinine 
(umol/L) 
Most 
recent 
Albumin 
Creatinine 
Ratio 
(mg/mmol) 
Length 
of 
follow 
up 
(years) 
180 M W S 3mo No presumed 
MCD 
(28mo) 
Na 2 N/A No N/A 
Pyloric 
stenosis, Single 
digit post-axial 
Polydactyly, 
Thrombocytosis 
Enalapril 
Cyclosporin, 
Tacrolimus, 
Prednisolone, 
Mycophenolate 
mofetil,  
32 
83 (serum 
albumin 
17g/L) 
9.08 
175 F W F 4mo Yes presumed 
Late 
Finnish 
type 
CNS 
(22mo) 
End 
stage 
of 
Finnish 
type 
CNS 
(26mo) 
Tx 1y9m Yes No No None 73 3.2 9.58 
175S F W F 1mo Yes presumed Na Na 1 Na Na Na 
mild peripheral  
branch 
pulmonary 
stenosis; 
Patent foramen 
ovale 
 Captopril,  24 
2160  
(serum 
albumin 
17g/L) 
2.33 
 
Table 1. Clinical features of the affected individuals with MAGI2 mutations. 
The following abbreviations are used: M – male, F – female;  mo – months; MCD – Minimal Change Disease, CNS – Congenital Nephrotic Syndrome; CKD – Chronic Kidney 
Disease; ESRF – End Stage Renal Failure; Tx – transplanted;  
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Figure 2. MAGI2 staining. 
Immunohistochemical staining with human anti-MAGI2 antibody (Sigma) is shown (20x). A - A kidney which was 
not suitable for transplant was used as a control, B - Biopsy specimen obtained from an individual with Minimal 
Change Disease, MAGI2 staining is seen in the glomeruli at the periphery of capillary loops, consistent with 
podocyte localisation. Staining in tubules is also seen. C - Nephrectomy specimen obtained from 175 
(homozygous mutation in MAGI2) shows weak but positive glomerular MAGI2 staining D - Biopsy specimen 
obtained from 180 (compound heterozygous mutation in MAGI2) shows complete lack of MAGI2. Black line 
indicates 100μm scale. 
 
 
Figure 3. Nephrin immunostaining on paraffin embedded renal tissue sections. 
Confocal microscopy images shows nephrin staining (green), DAPI nuclear staining in blue. A – positive control, 
normal human kidney; B – negative control (no nephrin antibody), normal human kidney; C - Nephrectomy 
specimen obtained from 175 (homozygous mutation in MAGI2); D - Biopsy specimen obtained from 180 
(compound heterozygous mutation in MAGI2). Top panel shows whole glomerulus (40x +/-3), bottom panel A, C, 
D, shows higher magnification (100x +/-7). Bottom panel shows decreased/disrupted nephrin expression 
between normal and patients’ podocytes.
15 
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